Advertisement
ELAB vs LPCN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and LPCN is a Hold.
ELAB in -4.24% downward trend, falling for three consecutive days on November 09, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ELAB declined for three days, in 229 of 236 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ELAB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAB advanced for three days, in 76 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ELAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.078) is normal, around the industry mean (3.498). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.250) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ELAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LPCN's RSI Indicator recovers from oversold territory
The RSI Indicator for LPCN moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 34 of the 39 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on LPCN as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for LPCN just turned positive on November 02, 2026. Looking at past instances where LPCN's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +12.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where LPCN advanced for three days, in 209 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
LPCN moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LPCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
LPCN broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LPCN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.595) is normal, around the industry mean (3.498). P/E Ratio (-0.849) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.302) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. LPCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LPCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LPCN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 72 | |
P/E GROWTH RATING 1..100 | 16 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ELAB | LPCN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 86% |
| Momentum ODDS (%) | N/A | 2 days ago 80% |
| MACD ODDS (%) | N/A | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 23 days ago 84% | 3 days ago 82% |
| Declines ODDS (%) | 3 days ago 90% | 20 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELAB’s FA Score shows that 0 FA rating(s) are green while LPCN’s FA Score has 1 green FA rating(s).
- ELAB’s FA Score: 0 green, 5 red.
- LPCN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELAB’s TA Score shows that 4 TA indicator(s) are bullish while LPCN’s TA Score has 4 bullish TA indicator(s).
- ELAB’s TA Score: 4 bullish, 2 bearish.
- LPCN’s TA Score: 4 bullish, 5 bearish.
Price Growth
ELAB (@Biotechnology) experienced а -12.89% price change this week, while LPCN (@Biotechnology) price change was +8.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ELAB is expected to report earnings on Nov 13, 2026.
LPCN is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ELAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with LPCN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then LPCN could also see price increases.
| Ticker / NAME | Correlation To ELAB | 1D Price Change % | ||
|---|---|---|---|---|
| ELAB | 100% | +6.96% | ||
| LPCN - ELAB | 42% Loosely correlated | -7.56% | ||
| LXRX - ELAB | 25% Poorly correlated | +2.20% | ||
| HURA - ELAB | 25% Poorly correlated | -9.04% | ||
| ERNA - ELAB | 24% Poorly correlated | -0.25% | ||
| MTNB - ELAB | 24% Poorly correlated | -0.81% | ||
More | ||||
LPCN and
Correlation & Price change
A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.
| Ticker / NAME | Correlation To LPCN | 1D Price Change % | ||
|---|---|---|---|---|
| LPCN | 100% | -7.56% | ||
| SPRY - LPCN | 63% Loosely correlated | +13.33% | ||
| HYFT - LPCN | 43% Loosely correlated | -4.63% | ||
| ELAB - LPCN | 42% Loosely correlated | +6.96% | ||
| ZNTL - LPCN | 36% Loosely correlated | +3.45% | ||
| GLSI - LPCN | 32% Poorly correlated | -2.72% | ||
More | ||||